{"id":5928,"date":"2018-06-15T01:00:00","date_gmt":"2018-07-27T08:47:37","guid":{"rendered":"http:\/\/www.05921.net\/index.php\/2018\/07\/27\/%e3%80%90%e5%85%a8%e7%90%83%e5%88%b6%e8%8d%af50%e5%bc%ba%e3%80%91pharm-execs-top-50-companies-2018\/"},"modified":"2018-07-27T16:47:41","modified_gmt":"2018-07-27T08:47:41","slug":"%e3%80%90%e5%85%a8%e7%90%83%e5%88%b6%e8%8d%af50%e5%bc%ba%e3%80%91pharm-execs-top-50-companies-2018","status":"publish","type":"post","link":"https:\/\/www.05921.net\/index.php\/5928\/","title":{"rendered":"\u3010\u5168\u7403\u5236\u836f50\u5f3a\u3011Pharm Exec's Top 50 Companies 2018"},"content":{"rendered":"
\n

\u8f89\u745e\u7a33\u5c45\u699c\u9996\uff0c\u4e24\u5bb6\u5370\u5ea6\u5236\u836f\u8fdb\u516550\u5f3a\uff0c\u592a\u9633\u5236\u836f\u548c\u9c81\u5bbe\u5236\u836f\u3002<\/p>\n


<\/p>\n

Pharm Exec\u2019s annual listing of the top biopharma players shows that most are holding their ground as they weigh a more challenging business climate with new opportunities for growth in a potentially resurgent marketplace .<\/p>\n

 <\/p>\n

Amid all the swirling changes in the biopharmaceutical and healthcare marketplaces\u2014from therapeutic advances on one side to access, pricing, and business pressures on the other\u2014our latest annual list of the top 50 global biopharma sales leaders remained remarkably stable. The first 10 spots on the ledger, once again led by Pfizer, were unchanged from the previous full-year rankings (see tables below). However, prescription sales gains among the entrenched stalwarts were relatively modest, on average, with Johnson & Johnson and Roche experiencing the largest increases at 7.6% and 5.5%, respectively. In assembling the data for the annual listing\u2014now in its 18th year\u2014Pharm Exec partnered again with life sciences market intelligence firm Evaluate Ltd.<\/p>\n

Sanofi, ranked fifth in sales, boosted its R&D spend the most among the top 10 holders, with a 46% jump in investment versus the previous year. The Paris-based company currently has 28 projects in Phase III development or seeking approval with regulators, and has six programs targeting rare diseases in Phase II or III clinical trials. It\u2019s no secret that, overall, industry investment in rare disease drugs\u2014on the investigative and commercial-expansion stages\u2014is on the rise. The FDA, for example, reportedly granted 77 orphan drug approvals last year and 476 orphan drug designation requests. <\/p>\n

Among the top 20 sales leaders on our list, other companies with notable spikes in R&D spending year-on-year include Gilead Sciences at 26.8%, Allergan at 69.5%, and Teva Pharmaceutical Industries, which more than doubled its output, investing $4.97 billion in R&D.<\/p>\n

Biopharma\u2019s bottom line in 2017 was impacted by US tax reform passed late in the year, which limited overall profit for some, with drugmakers having to pay large one-time charges related to the changes. Going forward, however, the tax reform, which lowered the income tax for US companies to 21%, is expected to spur a resurgence in life sciences M&A. It may already have, with several smaller-scale acquisitions announced by big pharma so far this year. Could such dealmaking, combined with larger, global moves, including Takeda\u2019s proposed $62 billion acquisition of Shire last month, rearrange some of the positioning in our Pharma 50 listing come next year? The Takeda-Shire combo would thrust the new organization into the top 10, reports say.<\/p>\n

Continued focus in political and other circles to curb drug pricing could influence the jockeying as well. Although it\u2019s difficult to gauge the immediate impact of some efforts, such as the US Administration\u2019s newly unveiled strategy to reform pricing, which didn\u2019t include specific timelines on policy implementation. What is more certain is the likely continued penetration of specialty drug products within the overall pharma market\u2014a factor that has contributed to higher prescription medicine costs, even as some reports have predicted branded drug spending in developed countries will actually fall this year and remain flat in the near-term.<\/p>\n

With all the different dynamics at play, the importance of having strong and stable leadership has perhaps never been more critical for biopharma. Which brings us again to this year\u2019s special Pharma 50 accompanying feature by guest authors at the executive search and talent advisory firm Russell Reynolds Associates. It\u2019s clear organizations today are facing mounting market pressures, as the traditional commercial model has become increasingly challenged. The old methods of leadership assessment, therefore, are now myopic, the authors contend, and new perspectives on identifying and benchmarking the character profile of effective C-suite leaders\u2014with the makeup to lead over the long term\u2014are needed. In the pages ahead, Russell Reynolds presents such an approach, using a framework of eight personality dimensions and applying them across all industries to extract those vital and distinctive leadership traits that will best predict \u201cC-suite durability\u201d in the world of biopharma.    <\/p>\n

See how the top 50 biopharma revenue generators in prescription drug sales stack up ahead (click on the tables to enlarge).<\/p>\n

 <\/p>\n

\"\u3010\u5168\u7403\u5236\u836f50\u5f3a\u3011Pharm<\/span>\"\u3010\u5168\u7403\u5236\u836f50\u5f3a\u3011Pharm\"\u3010\u5168\u7403\u5236\u836f50\u5f3a\u3011Pharm<\/span><\/span><\/span>\"\u3010\u5168\u7403\u5236\u836f50\u5f3a\u3011Pharm<\/span>\"\u3010\u5168\u7403\u5236\u836f50\u5f3a\u3011Pharm<\/span><\/p>\n

 <\/p>\n

Recommended Reading<\/h2>\n